Estrogen metabolism and mammographic density in postmenopausal women : a cross-sectional study by B.J. Fuhrman et al.
Estrogen metabolism and mammographic density in
postmenopausal women: a cross-sectional study
Barbara J. Fuhrman1, Louise A. Brinton1, Ruth M. Pfeiffer2, Xia Xu3, Timothy D. Veenstra3,
Barbara E. Teter4, Celia Byrne5, Cher M. Dallal1, Maddalena Barba6, Paola C. Muti6, and
Gretchen L. Gierach1
1Hormonal and Reproductive Epidemiology Branch, Division of Cancer Epidemiology and
Genetics, National Cancer Institute, National Institutes of Health, Department of Health and
Human Services, Bethesda, MD, USA
2Biostatistics Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute,
National Institutes of Health, Department of Health and Human Services, Bethesda, MD, USA
3Laboratory of Proteomics and Analytical Technologies, Advanced Technology Program, SAIC-
Frederick, Inc., National Cancer Institute at Frederick, Frederick, MD 21702.
4University at Buffalo, Buffalo, NY, USA
5Uniformed Services University, Bethesda MD, USA
6Juravinski Cancer Center, McMaster University, Hamilton, ON, Canada.
Abstract
Background—Prospective studies have consistently found that postmenopausal breast cancer
risk increases with circulating estrogens; however, findings from studies of estrogens and
mammographic density (MD), an intermediate marker of breast cancer risk, have been
inconsistent. We investigated the cross-sectional associations of urinary estrogens, and their 2-, 4-,
and 16-hydroxylated metabolites with MD.
Methods—Postmenopausal women without breast cancer (n=194), ages 48-82 years, and
reporting no current menopausal hormone therapy use were enrolled at a clinic in Western NY in
2005. Urinary estrogens and estrogen metabolites were measured using mass spectrometry.
Percent MD and dense area (cm2) were measured using computer-assisted analyses of digitized
films. Linear regression models were used to estimate associations of log-transformed estrogen
measures with MD while adjusting for age, body mass index (BMI), parity, and past hormone
therapy use.
Results—Urinary concentrations of most individual estrogens and metabolites were not
associated with MD; however, across the interdecile range of the ratio of parent estrogens (estrone
and estradiol) to their metabolites, MD increased by 6.8 percentage points (p=0.02) and dense area
increased by 10.3 cm2 (p=0.03). Across the interdecile ranges of the ratios of 2-, 4-, and 16-
hydroxylation pathways to the parent estrogens, MD declined by 6.2 (p=0.03), 6.4 (p=0.04), and
5.7 (p=0.05) percentage points, respectively. All associations remained apparent in models without
adjustment for BMI.
Conclusions—In this study of postmenopausal women, less extensive hydroxylation of parent
estrogens was associated with higher MD.
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Impact—Hydroxylation of estrogens may modulate postmenopausal breast cancer risk through a
pathway involving MD.
Keywords
Estrogens; metabolism; mammography; breast neoplasms; risk factors; human; female; middle-
aged
INTRODUCTION
Estrogens play important roles in the pathophysiology of breast tumors and are recognized
as causal etiologic factors. This central insight has led to many of the available preventive
and therapeutic interventions for breast cancer. Numerous laboratory and small
observational studies have suggested that estrogen metabolism may also play a role in breast
cancer risk and that its study could provide clues about underlying mechanisms of estrogen-
mediated carcinogenesis (reviewed in (1)).
Because estrogens can enhance cellular proliferation through receptor-mediated signaling, it
is plausible that elevated estrogen levels may be associated with a greater extent of
radiodense breast tissues. Mammographic density (MD), a measure of the extent of
radiodensity, has consistently been associated with both breast cancer risk (2-4) and many
established risk factors (5). That estrogens could increase breast cancer risk through effects
on MD is supported by observations that menopausal hormone therapy use, known to
increase breast cancer risk, is associated with increased MD (6), while tamoxifen, a selective
estrogen-receptor modulator used to prevent breast cancer, often results in decreased MD
(7). While prospective studies have consistently found that postmenopausal breast cancer
risk increases with circulating estrogens (8), the analogous relation has not consistently been
observed for MD (9-19).
The parent estrogens, estrone and estradiol, can each be hydroxylated at the C2, C4, or C16
positions of the steroid ring to produce an array of metabolites (Figure 1) with different
affinities for estrogen receptors (20). Catechol estrogens, characterized by adjacent hydroxyl
groups, can be oxidized to form mutagenic semi-quinones (21), while methylation prevents
formation of these reactive species (22). Wide inter-individual variation in estrogen
metabolism results in diverse exposure profiles (23).
The systematic study of estrogen metabolites has become possible with the development of a
highly reliable liquid chromatography-tandem mass spectrometry (LC-MS/MS) assay for
concurrent measurement of 15 estrogens and estrogen metabolites (jointly referred to as
EM) in urine or serum (24, 25). A recent prospective study utilizing this assay identified two
patterns of estrogen metabolism associated with reduced postmenopausal breast cancer risk
even after adjusting for estradiol: greater extent of 2-hydroxylation of parent estrogens and
greater methylation of 4-pathway catechol estrogens (26). Riza and colleagues (27) used an
immunoassay and found elevated urinary concentrations of 2-hydroxyestrone and a higher
ratio of this metabolite to 16α-hydroxyestrone in association with higher risk MD patterns.
We measured urinary EM using LC-MS/MS within a cross-sectional study of
postmenopausal women to examine whether estrogens, estrogen metabolites, or patterns of
estrogen metabolism are associated with MD.
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METHODS
Study Design and Population
We conducted a cross-sectional study of MD and its determinants, with a focus on dietary
and hormonal exposures (28). Participants were enrolled when they sought mammograms at
a radiology clinic near Buffalo, NY between March-August 2005. Eligible subjects had to be
at least 45 years old and postmenopausal at study entry (last menstrual period > 12 months
prior or a history of bilateral oophorectomy; for those with a history of hysterectomy and at
least one intact ovary, menopause was defined as age > 51 years). Women who reported a
history of cancer other than non-melanoma skin cancer, use of menopausal hormone therapy
or antibiotics within the previous month, a history of breast augmentation or breast reduction
surgery, or an allergy to soy or peanuts (the protocol included a soy challenge to determine
equol status) were excluded from the study. Participants completed a questionnaire,
underwent anthropometric measures by trained personnel, provided first morning urine
specimens before undergoing a soy challenge, and provided access to mammographic films.
Of 330 enrolled women, 24 were later excluded: 10 who received digital, rather than film-
screen, mammograms; 9 who were premenopausal, 2 who were taking menopausal
hormones, and 3 who were diagnosed with breast cancer. Urine specimens were available
for 212 of the 306 eligible participants; others either did not provide a morning urine sample
prior to a soy intervention (n=68) or did not give consent for future research (n=26). Of
those remaining, we excluded those who had unavailable questionnaires (n=11),
anthropometric measures (n=2), mammographic films (n=3), or urinary EM measures (n=2).
Thus, 194 participants remain in the present analysis.
Urine Collection
Participants provided first-morning urine samples, collected between 6-8 a.m. at home and
delivered to the clinic with an icepack, usually by 10 a.m. Urine samples were filtered and
aliquoted into 2.0 mL cryovials and stored at −80 °C. Urinary EM have previously been
observed to remain stable under similar conditions of processing and storage (29). Urinary
creatinine was measured to adjust for variation in urine volumes (28).
Laboratory Assays
LC-MS/MS was used to measure 15 urinary EM, as shown in Figure 1 (24). Details of the
method, including sample preparation and assay conditions, have been published previously
(24). We used six stable isotopically labeled standards to account for losses during sample
preparation and assays: deuterated 2-hydroxyestradiol, 2-methoxyestradiol and estriol (C/D/
N Isotopes, Inc., Pointe-Claire, Quebec, Canada); deuterated 16-epiestriol (Medical
Isotopes, Inc., Pelham, NH); and 13C-labeled estrone and estradiol (Cambridge Isotope
Laboratories, Andover, MA). Assay reliability was monitored using 10% masked quality
control (QC) samples inserted randomly into each batch. Coefficients of variation were <5%
for each measured EM.
Measurement of Mammographic Density (MD)
Right and left cranio-caudal films were selected for measurement. Mammographic films
were collected and then digitized at 100 pixels / cm with a Kodak Lumisys 85 laser film
scanner, which covers an optical density range of 0 - 4.0 absorbance. MD was measured by
a single reader (B.T.) using computer-assisted analysis to quantify total breast area (cm2),
and dense area (cm2) (30); MD measures for each woman represent means of the measures
for left and right breasts. Percent density was calculated as 100*dense area / total area.
Comparisons of repeated measures for 10% of the films yielded overall coefficients of
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variation of 8.5% and 8.8%, for percent density and dense area, respectively, and intra-class
correlation coefficients of 0.95 and 0.89.
Estrogen Measurements
MD associations were evaluated for each individual EM and for groups based on metabolic
pathways. We also investigated ratios representing measures of individual propensities for
site-specific hydroxylation of parent estrogens and for methylation of 2- and 4-pathway
catechols. Ratios of competing metabolic pathways, in particular, the ratio of 2- to 16-
hydroxylation pathways were investigated because they have been studied in association
with breast cancer (31-33) and MD (27).
Statistical Analysis
Neither percent density nor its log or square root transformation were normally distributed;
therefore we used it without transformation. In contrast, dense area and total area did not
deviate from normality. The main independent variables were urinary concentrations of EM
in picomoles per milligram of creatinine. Following log-transformation, distributions of
estrogens and estrogen metabolite concentrations did not deviate significantly from
normality. We examined the correlation among urinary EM using Pearson’s correlation
coefficients. Associations of MD measures with participant characteristics were evaluated
by testing for differences across categories using analysis of variance (ANOVA), or t-tests,
as appropriate.
Linear regression models were used to evaluate associations of each EM with percent
density, dense area, and total area. For regression models, all estrogen metabolism measures
were log transformed to a base corresponding to the ratio of the 90th to the 10th percentile
observed for that measure. This was done so that the regression coefficients associated with
each estrogen, metabolite, group or ratio correspond to the average change in density across
its interdecile range; thus, regression coefficients are comparable across measures in spite of
differences in scale. Residuals from linear models were assessed by visual inspection and
were not found to deviate substantially from normality.
Breast cancer risk factors were evaluated as potential confounders of EM associations with
MD using stepwise linear models. Final multivariable-adjusted models included continuous
age and BMI, combined parity and age at first birth ( nulliparous, parous < 21 y; parous
22-29 y; parous 30+ y) and past use of combination menopausal hormone therapy (former,
never). The proportion of variation in density measures attributable to estrogen metabolism
was assessed by adding EM to final adjusted models and observing the change in the model
R-square. The impact of adiposity on any estrogen-density associations was assessed by
comparing results from regression models with and without BMI.
To evaluate whether associations of EM were modified by factors known to influence
estrogens and/or MD, we stratified analyses by age, years since menopause, BMI, parity,
and past use of menopausal hormones. We calculated Wald p-values for interaction by
including interaction terms in regression models.
Scatterplots with a fitted line were created for associations of estrogens with the
multivariable-adjusted percent density. In sensitivity analyses, women with indications other
than routine screening for mammography and those reporting histories of surgical
menopause were excluded; results were similar and are not shown here.
P-values <0.05 were considered statistically significant. All tests were two-sided. Analyses
were conducted using SAS v. 9.1 (SAS Institute, Cary, NC).
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RESULTS
In this sample of 194 postmenopausal women, the mean (standard deviation, SD) age was
58 (6) years. Most participants were non-Hispanic and white (98%), and 92% reported
seeking a routine screening mammogram. The mean (SD) percent density was 34.3 (17.7);
median percent density was 38.8, and the range was 3.0 to 77.0. Mean (SD) dense area was
49.0 (27.2) cm2 and mean (SD) total area was 145.7 (60.5) cm2. Characteristics of the study
participants and associations with MD are shown in Table 1. Thirty-four percent of
participants were overweight (BMI 25.0-29.9) and 35% were obese (BMI >30.0). Only 15%
of participants were nulliparous and 69% had a first full-term birth before 30 years of age. In
this study sample 63% of participants reported past use of menopausal hormones, and 33%
combination menopausal hormones (estrogen + progesterone).
Percent MD declined with increasing age, BMI, and years since menopause, and was higher
in women who were nulliparous or had first births after age 30y. Histories of natural vs.
surgical menopause, and past vs. never use of combination menopausal hormone therapy
were each associated with higher percent density. Among these factors, only past use of
combination menopausal hormone therapy was statistically significantly associated with
increased dense area; in contrast, BMI, surgical menopause and years since menopause were
positively associated with total breast area.
Table 2 shows medians and interdecile ranges for each urinary EM. On average, parent
estrogens represented 16% of total urinary estrogens, while 2-, 4-, and 16-hydroxylated
metabolites represented, respectively, 32%, 5%, and 43% of total urinary estrogens. Log-
transformed urinary concentrations of EM were moderately to highly correlated. The
Pearson correlation coefficients for associations of the parent estrogens with total estrogens
and metabolites, and with the 2-, 4-, and 16-hydroxylation pathways were 0.77, 0.52, 0.44,
and 0.57, respectively.
Multivariable-adjusted linear associations of log-transformed measures of EM with percent
density, dense area, and total area are also presented in Table 2. Estrone and estradiol were
not statistically significantly associated with any measure of MD. While most EM were not
significantly associated with percent density or dense area, in general, parent estrogens were
positively associated, and estrogen metabolites in the 2-, 4-, and 16-hydroxylation pathways
were inversely associated with percent density. Across the interdecile range of 2-
methoxyestrone, percent MD declined significantly by 7.7 percentage points (p=0.01) and
dense area declined by 8.7 cm2 (p=0.09); similar associations were noted for 4-
methoxyestrone.
An increased ratio of parent estrogens to estrogen metabolites was associated with higher
MD; across the interdecile range of this ratio, mean percent MD increased by 6.8 percentage
points (p=0.02) and mean dense area increased by 10.3 cm2 (p=0.03) (Table 2). After
adjusting for covariates, the ratio of parent estrogens to estrogen metabolites accounted for
2.1% of the variation in percent density, and 2.4% of the variation in dense area. Ratios of
2-, 4-, and 16-hydroxylation pathways to parent estrogens were each inversely associated
with percent density (p=0.03, 0.04, 0.05, respectively) and dense area (p=0.02, 0.03, and
0.05, respectively). Ratios of 2- to 16-pathways, and of 2-hydroxyestrone to 16α-
hydroxyestrone were not significantly associated with any measure of MD. No statistically
significant associations were observed between any EM measure and total area (cm2) of the
breast. Observed multivariable-adjusted associations were similar in direction and
magnitude to univariate associations (data not shown).
BMI was directly correlated with urinary estrone (Pearson’s r=0.24, p=0.0008) and inversely
correlated with percent MD (r=−0.39, p<0.0001, not shown). Results from adjusted models
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that did and did not include BMI showed similar results (data not shown). Regression
coefficients for statistically significant findings in Tables 2 and 3 did not vary by >10%
based upon the decision to include or exclude BMI, nor did the decision to include or
exclude BMI modify their statistical significance.
Associations of EM profiles with percent MD were significantly modified by BMI and years
since menopause (Table 3). When results were stratified on BMI (>30.0 or <30.0), MD
increased by 15.3 percentage points across the interdecile range of estrone (p=0.005) and by
12.5 percentage points across the interdecile range of estradiol (p=0.03) among obese
women , but estrone and estradiol were not associated with density in non-obese women
(pinteraction=0.02, and 0.19, respectively). Accordingly, in obese women MD increased by
16.8 percentage points across the interdecile range of the ratio of parent estrogens to
estrogen metabolites (p<0.002); this ratio accounted for 12.6% of the variation in percent
MD. Accordingly, in obese women MD declined by 16.4, 17.4, and 13.2 percentage points
across the interdecile ranges of ratios of 2-, 4-, and 16-pathways to parent estrogens (with
p<0.002, p<0.002, and p=0.009, respectively). These associations were not observed in non-
obese women (pinteraction =0.0496, pinteraction=0.03, and pinteraction=0.02, respectively)
(Table 3). Associations of the ratio of the 2-hydroxylation pathway to the parent estrogens in
obese women and their non-obese counterparts are illustrated in Supplementary Figure 1.
Among women with menopause <8 years before baseline, MD increased by 7.4 percentage
points across the interdecile range of estrone (p=0.03), and 9.6 percentage points across the
interdecile range of estradiol (p=0.02); these associations were not observed in women with
a more distant menopause (pinteraction=0.01, and 0.004, respectively) (Table 3). In women
with more recent menopause, MD increased by 14.0 percentage points across the interdecile
range of the ratio of parent estrogens to estrogen metabolites (p<0.0001); the ratio of parent
estrogens to estrogen metabolites accounted for 9.6% of the variation in percent MD. In the
same group, MD declined by 15.5, 15.7, and 10.7 percentage points across the interdecile
ranges of the ratios of 2-, 4-, and 16-pathways to parent estrogens (with p<0.0001,
p<0.0001, and p=0.005, respectively). These associations were not observed in women with
menopause >8 years prior (pinteraction=0.02, 0.0006, 0.002, and 0.14, respectively) (Table
3).
Associations of 2- to 16-pathways, and of 2-hydroxyestrone to 16α-hydroxyestrone with
percent density were not significantly modified by BMI; however, there was some
suggestion that the association of the ratio of 2- to 16 pathways with percent MD was
modified by years since menopause (pinteraction= 0.02). In women with more recent
menopause, the ratio of 2- to 16-pathway estrogen metabolites was associated with non-
significant lower percent density (β=−7.3, p=0.07), while among women with more distant
menopause, the same ratio was non-significantly associated with higher percent density
(β=5.5, p=0.21).
While groups defined by BMI and years since menopause overlap, no statistically significant
association between BMI and years since menopause was observed (data not shown).
Although the subgroup findings could suggest that the associations are present only in
postmenopausal women with more recent or sustained exposure to higher circulating
estrogens, we observed no statistically significant differences in total EM across subgroups
defined by years since menopause and obesity (data not shown). No statistically significant
modification of these associations was noted by latency of hormone therapy use (data not
shown).
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No significant interactions were observed for other factors investigated (data not shown),
including age, parity/age at first birth, type of menopause, previous use of menopausal
hormone therapy and years since last use of menopausal hormone therapy.
DISCUSSION
Among postmenopausal women, we observed no overall associations for individual
estrogens or for most estrogen metabolites. However, urinary concentrations of the most
prevalent methylated catechols, 2-methoxyestrone and 4-methoxyestrone, were each
inversely associated with MD. We observed statistically significant direct associations
between percent MD and the ratio of parent estrogens to all estrogen metabolites, suggesting
that less extensive hydroxylation may be associated with higher MD. Similar associations
were observed between this ratio and dense area, suggesting that the association between
percent density and estrogen metabolism is mediated through differences in dense area. The
inverse associations between ratios of the 2-, 4-, and 16-hydroxylation pathways to parent
estrogens with percent MD and dense area did not differ markedly by metabolic pathway,
suggesting a protective role for hydroxylation by any pathway. In addition, these
associations remained apparent in models with and without adjustment for BMI, suggesting
that adiposity is neither a confounder of the association nor is it on the causal pathway of
estrogen metabolism to MD.
Nine previous studies have cross-sectionally assessed associations between circulating
estrogens (including estrone, estradiol, estrone sulfate, and free estradiol) and MD in
postmenopausal women (9-17, 19). In these studies, immunoassays were used to measure
estrogens in serum or plasma, and quantitative or semi-quantitative measures were used to
characterize MD. The studies have diverse results; in six studies (9, 10, 12, 15, 17, 19)
inverse associations between circulating estrone or estradiol and percent MD were observed;
but, in three of these, the associations were attenuated and no longer statistically significant
following adjustment for a measure of adiposity (12, 15, 19). A single study found no
statistically significant associations of MD with plasma estrogens (13). In three studies,
investigators found positive associations between estrogens and MD after adjustment for
BMI (11, 14, 16).
These inconsistent finding s may be attributable to sampling variation but alternatively,
could reflect an underlying heterogeneity in the association. In the present study,
associations of MD with parent estrogens and with the ratios of parent estrogens to their
metabolites were strongly apparent in two overlapping but uncorrelated subgroups. The ratio
of parent estrogens to all metabolites was stronger in obese women and those with a recent
menopause. These subgroup findings may be due to chance but should be considered in
future studies. It is notable that in one previous study which found a direct association of
estrogens with MD, the participants reported very recent menopause (with a mean of 15
months prior to their mammogram) (16).
In a previous study of estrogen metabolites and MD in postmenopausal women, Riza and
colleagues (27) considered urinary 2-hydroxyestrone, 16α-hydroxyestrone, and their ratio in
association with qualitatively-assessed low- (n=70) and high-risk (n=70) Wolfe
mammographic parenchymal patterns They observed strong direct associations of risk with
2-hydroxyestrone and the ratio of 2-hydroxyestrone to 16-hydroxyestrone. In contrast, we
observed no associations with MD for 2-hydroxyestrone, 16-α hydroxyestrone, their ratio,
or the ratio of their corresponding pathways. The study by Riza et al. relied on an
immunoassay to measure estrogen metabolites; recognized limitations in the specificity,
sensitivity, and reproducibility of this type of assay could bias results towards the null but
would not explain the distinct pattern of their findings (34).
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In our study, MD decreased significantly as urinary concentrations of some methylated
catechols increased. Methylation of catechol estrogens reduces their estrogenicity and
prevents their conversion to reactive quinones (35). This finding is consistent with that from
the first prospective study of postmenopausal breast cancer to study serum EM using the
LC-MS/MS method, which suggested that greater 2-hydroxylation of parent estrogens was
associated with reduced risk of breast cancer (36). In the same study, investigators found
increasing risk of breast cancer associated with the ratio of the 4-hydroxylated catechol to
the methylated catechols (36). In contrast, we did not observe any significant associations
between measures of MD and ratios of catechols to methylated catechols in the 4-
hydroxylation pathways. Differences between these findings could be attributable to
sampling variation, use of an intermediate marker rather than a breast cancer endpoint, or
differences between urinary and circulating EM profiles.
While MD has been shown to be highly heritable (37), only a few genetic variants are
strongly and consistently associated with this phenotype. In a meta-analysis of five genome-
wide association studies of MD, polymorphic variants in ZNF365 (rs10995190), ESR1
(rs2046210), and LSP1 (rs3817198) were associated with percent density (38). A recent
pooled analysis of 19 studies from 10 countries identified associations of LSP1 (rs3817198)
with both percent density and dense area, and of RAD51L1 (rs10483813) with percent
density (39). Although numerous studies have examined genes in pathways that regulate
estrogen synthesis and metabolism in relation to MD, these have produced largely
conflicting results (37). Ongoing consortial efforts will provide better powered tests of
hypotheses about the genes involved in estrogen metabolism and MD.
Our study has a number of strengths, including urinary EM profiles representing a detailed
assessment of metabolic phenotypes that are accurate and reproducible in postmenopausal
women. MD was measured quantitatively, showed good reproducibility and was associated
with covariates as expected. Continuous exposures and outcomes result in good power to
detect associations with even modest sample sizes. Study limitations, however, include the
concern that urinary EM may not represent relative or absolute levels in circulation or in
breast tissue, and that some EM may be excreted via bile rather than urine. Our MD
measures were based on a 2-dimensional area; volumetric density measures may yet prove
to be more accurate predictors of breast cancer risk (40). However, quantitative, computer-
assisted measures of percent MD have previously been shown to be a reproducible and
robust marker of breast cancer risk (41). We had limited power to detect interactions,
particularly by multilevel covariates. Further, the exclusion of current users of hormone
therapy, although customary in studies of endogenous hormones, may limit the
generalizability of findings (42). We have not adjusted for multiple comparisons due to the
exploratory nature of the study.
In summary, our findings suggest that greater urinary excretion of parent estrogens
compared with metabolites may be associated with higher MD in postmenopausal women.
This suggests that increased hydroxylation of parent estrogens may protect against breast
cancer through a causal pathway that includes MD. Our data also suggest that the
association of estrogens and MD is maintained only among postmenopausal women with
recent or sustained exposure to higher levels of circulating estrogens (such as occurs close to
the time of menopause or among obese women). Future larger studies are needed to explore
these potential interactions in more detail.
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Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Pathways of estrogen metabolism
Adapted from Ziegler et al. (43) and reproduced with permission from Environmental
Health Perspectives.
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